Why Nanoparticle Fill-Finish Is Different Aseptic fill-finish for a conventional small molecule injectable involves filling a solution into vials under Grade A conditions and sealing them. The process is technically demanding from a contamination control perspective, but the drug product itself is chemically robust enough to withstand the shear forces, surface contacts, and process-related stresses […]

Beyond the Simple Solution The simplest injectable drug product is a solution: the API is fully dissolved in a compatible aqueous vehicle, the solution is sterile filtered, and it is filled into vials or prefilled syringes. A significant proportion of the injectable pipeline, however, cannot be formulated as simple solutions. Poorly water-soluble APIs, APIs that […]

Why Biologics Need Lyophilisation Proteins, monoclonal antibodies, enzymes, and other biological molecules are inherently unstable in aqueous solution. In solution, they are subject to hydrolysis, oxidation, deamidation, aggregation, and physical denaturation, degradation pathways that can reduce potency, alter immunogenicity, and compromise the safety of the product. For biologics with an intended shelf life of two […]

The High Stakes of Sterile Manufacturing A sterile injectable drug product that is contaminated with microorganisms or particulates can cause a patient serious harm or death. There is no sterilisation step at the end of aseptic fill-finish manufacturing: the product must be sterile when it is filled and sealed, and it must remain sterile throughout […]

Why Bioequivalence Studies Depend on Exceptional Analytical Quality A bioequivalence (BE) study answers one specific question: does a test formulation, whether a generic product, a reformulated branded product, or a product manufactured at a new site, deliver the same drug exposure to the body as the reference formulation? The answer is expressed in terms of […]

A Growing Category in Drug Development Controlled substances have moved from the margins of pharmaceutical development to its centre. Psychedelic-assisted therapy programmes involving psilocybin, MDMA, and ketamine derivatives are advancing through Phase II and Phase III trials. Cannabis-derived medicines, opioid alternatives, and GABA-modulating compounds for neurological conditions all involve scheduled molecules. The renaissance of interest […]

Why Stability Data Is Non-Negotiable Every regulatory filing for a drug substance or drug product, from the earliest IND or IMPD through to a marketing authorisation application, requires stability data. That data answers one fundamental question: for how long can the product be stored under defined conditions and remain within specification? The answer determines the […]

Why Concentration Data Alone Is Not Enough A bioanalytical study produces concentration-time data: measurements of drug (and sometimes metabolite) levels in biological matrices at defined timepoints. That data is necessary, but on its own it does not answer the questions that matter for drug development. How does exposure change with dose? What is the relationship […]

The Last Mile Problem in Clinical Supply A clinical trial can have the most rigorous bioanalytical programme and the most carefully designed protocol in the world, but if the investigational medicinal product (IMP) does not arrive at the investigator site in the right condition, at the right time, and with the right documentation, none of […]

What Flow Cytometry Offers That Other Techniques Cannot Flow cytometry measures multiple physical and chemical characteristics of individual cells as they pass, one by one, through a laser beam. Each cell scatters light in a pattern determined by its size and internal complexity, and emits fluorescence from labelled antibodies or other probes bound to specific […]

Biomarkers Are No Longer Optional in Drug Development A decade ago, biomarkers were an add-on to many clinical development programmes: interesting, potentially informative, but rarely central to regulatory decision-making. That has changed. The growth of precision medicine, the expansion of companion diagnostic requirements, and the increasing use of biomarker-defined patient populations in oncology and rare […]

Why Immunogenicity Matters for Biologic Drugs Biologic drugs, including monoclonal antibodies, fusion proteins, ADCs, and gene therapy vectors, are structurally complex molecules derived from biological systems. When administered to patients, they can trigger an immune response. The body may produce antibodies directed against the therapeutic molecule itself: anti-drug antibodies, or ADAs. The clinical consequences of […]